PPP4R1

Summary

PPP4R1 (protein phosphatase 4 regulatory subunit 1, HGNC:9320) is a protein-coding gene on chromosome 18p11.22, encoding Serine/threonine-protein phosphatase 4 regulatory subunit 1 (Q8TF05). Regulatory subunit of serine/threonine-protein phosphatase 4.

This gene encodes one of several alternate regulatory subunits of serine/threonine protein phosphatase 4 (PP4). The protein features multiple HEAT repeats. This protein forms a complex with PP4RC. This complex may have a distinct role from other PP4 complexes, including regulation of HDAC3 (Zhang et al., PMID: 15805470). There is also a transcribed pseudogene on chromosome 20. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 9989 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 147 total
• MANE Select transcript: NM_001042388

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9320
Approved symbol	PPP4R1
Name	protein phosphatase 4 regulatory subunit 1
Location	18p11.22
Locus type	gene with protein product
Status	Approved
Aliases	PP4R1
Ensembl gene	ENSG00000154845
Ensembl biotype	protein_coding
OMIM	604908
Entrez	9989

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 16 protein_coding, 9 retained_intron, 9 protein_coding_CDS_not_defined, 4 nonsense_mediated_decay

ENST00000285124, ENST00000400555, ENST00000400556, ENST00000577393, ENST00000577667, ENST00000577779, ENST00000578010, ENST00000578178, ENST00000578329, ENST00000578557, ENST00000578875, ENST00000579415, ENST00000579609, ENST00000579638, ENST00000580182, ENST00000580283, ENST00000580583, ENST00000580745, ENST00000581250, ENST00000581835, ENST00000582240, ENST00000582594, ENST00000582933, ENST00000583092, ENST00000583438, ENST00000583903, ENST00000583988, ENST00000584074, ENST00000584754, ENST00000886291, ENST00000886292, ENST00000886293, ENST00000924156, ENST00000924157, ENST00000962495, ENST00000962496, ENST00000962497, ENST00000962498

RefSeq mRNA: 3 — MANE Select: NM_001042388 NM_001042388, NM_001382562, NM_005134

CCDS: CCDS42412, CCDS42413

Canonical transcript exons

ENST00000400556 — 20 exons

Exon	Start	End
ENSE00002715633	9614478	9614559
ENSE00003472228	9550278	9550398
ENSE00003474614	9549197	9549338
ENSE00003477022	9557221	9557382
ENSE00003480924	9577064	9577191
ENSE00003489746	9584721	9584828
ENSE00003490023	9561980	9562075
ENSE00003505456	9588711	9588853
ENSE00003507063	9588089	9588235
ENSE00003525121	9559419	9559604
ENSE00003526742	9593768	9593874
ENSE00003551135	9583117	9583275
ENSE00003556376	9570157	9570683
ENSE00003559214	9614226	9614270
ENSE00003587675	9553322	9553422
ENSE00003639572	9584515	9584580
ENSE00003665821	9563378	9563550
ENSE00003682470	9595018	9595153
ENSE00003693738	9550052	9550186
ENSE00003908734	9546794	9547952

Expression profiles

Bgee: expression breadth ubiquitous, 299 present calls, max score 98.98.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.5387 / max 356.7320, expressed in 1813 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
171179	16.3197	1808
171181	1.5509	993
171180	1.3017	845
171178	0.3665	153

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	98.98	gold quality
esophagus squamous epithelium	UBERON:0006920	98.62	gold quality
gingival epithelium	UBERON:0001949	98.44	gold quality
tongue squamous epithelium	UBERON:0006919	98.42	gold quality
squamous epithelium	UBERON:0006914	98.41	gold quality
gingiva	UBERON:0001828	98.37	gold quality
epithelium of esophagus	UBERON:0001976	98.32	gold quality
pharyngeal mucosa	UBERON:0000355	97.60	gold quality
visceral pleura	UBERON:0002401	97.57	gold quality
male germ cell	CL:0000015	97.53	gold quality
calcaneal tendon	UBERON:0003701	97.52	gold quality
esophagus mucosa	UBERON:0002469	97.35	gold quality
lower esophagus mucosa	UBERON:0035834	97.35	gold quality
oral cavity	UBERON:0000167	97.29	gold quality
amniotic fluid	UBERON:0000173	97.24	gold quality
colonic epithelium	UBERON:0000397	97.22	gold quality
cervix squamous epithelium	UBERON:0006922	97.13	gold quality
ventricular zone	UBERON:0003053	97.10	gold quality
nasal cavity epithelium	UBERON:0005384	97.07	gold quality
epithelium of nasopharynx	UBERON:0001951	96.98	gold quality
nasopharynx	UBERON:0001728	96.96	gold quality
pleura	UBERON:0000977	96.78	gold quality
pancreatic ductal cell	CL:0002079	96.77	gold quality
cervix epithelium	UBERON:0004801	96.62	gold quality
secondary oocyte	CL:0000655	96.60	gold quality
parietal pleura	UBERON:0002400	96.60	gold quality
bronchial epithelial cell	CL:0002328	96.58	gold quality
epithelium of bronchus	UBERON:0002031	96.54	gold quality
ganglionic eminence	UBERON:0004023	96.48	gold quality
bronchus	UBERON:0002185	96.40	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	15.41

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

83 targeting PPP4R1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-8067	99.86	69.59	2260
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-370-5P	99.78	66.81	706
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-3177-5P	99.65	70.38	1174
HSA-MIR-762	99.58	66.61	1994

Literature-anchored findings (GeneRIF, showing 7)

• PP4R1 expression was triggered upon activation and proliferation of primary human T lymphocytes and deficiency for PP4R1 caused sustained and increased IKK activity, T cell hyperactivation, and aberrant NF-kappaB signaling in NF-kappaB-addicted T cell lymphomas (PMID:23084358)
• PP4R1 could mediate the dephosphorylation of TRAF2 Ser11. (PMID:25134449)
• Data identify PP4R1 as a novel target for virus subversion of the host anti-viral response. (PMID:28445980)
• PP4R1 interacts with HMGA2 to promote non-small-cell lung cancer migration and metastasis via activating MAPK/ERK-induced epithelial-mesenchymal transition. (PMID:32077156)
• PP4R1 accelerates the malignant progression of NSCLC via up-regulating HSPA6 expression and HSPA6-mediated ER stress. (PMID:37739270)
• PP4R1 promotes glycolysis and gallbladder cancer progression through facilitating ERK1/2 mediated PKM2 nuclear translocation. (PMID:38301910)
• AMBRA1 promotes intestinal inflammation by antagonizing PP4R1/PP4c mediated IKK dephosphorylation in an autophagy-independent manner. (PMID:38424148)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppp4r1	ENSDARG00000101316
mus_musculus	Ppp4r1	ENSMUSG00000061950
rattus_norvegicus	Ppp4r1	ENSRNOG00000013733
drosophila_melanogaster	Pp2A-29B	FBGN0260439
caenorhabditis_elegans	ppfr-1	WBGENE00008878

Paralogs (2): PPP2R1A (ENSG00000105568), PPP2R1B (ENSG00000137713)

Protein

Protein identifiers

Serine/threonine-protein phosphatase 4 regulatory subunit 1 — Q8TF05 (reviewed: Q8TF05)

All UniProt accessions (10): Q8TF05, F8WAJ9, J3KRU1, J3KSB0, J3KSH2, J3KSS1, J3QL26, J3QLA6, J3QQV0, J3QRV2

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory subunit of serine/threonine-protein phosphatase 4. May play a role in regulation of cell division in renal glomeruli. The PPP4C-PPP4R1 PP4 complex may play a role in dephosphorylation and regulation of HDAC3. Plays a role in the inhibition of TNF-induced NF-kappa-B activation by regulating the dephosphorylation of TRAF2. (Microbial infection) Participates in merkel polyomavirus-mediated inhibition of NF-kappa-B by bridging viral small tumor antigen with NEMO.

Subunit / interactions. Serine/threonine-protein phosphatase 4 (PP4) occurs in different assemblies of the catalytic and one or more regulatory subunits. Component of the PP4 complex PPP4C-PPP4R1. Interacts with HDAC3. (Microbial infection) Interacts with merkel polyomavirus small tumor antigen; this interaction bridges small tumor antigen with NEMO to inhibit NF-kappa-B.

Tissue specificity. Widely expressed with high expression in cultured mesangial cells. Isoform 1 and isoform 2 are expressed in renal tissues.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TF05-1	1, PP4Rmeg	yes
Q8TF05-2	2

RefSeq proteins (3): NP_001035847, NP_001369491, NP_005125 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000357	HEAT	Repeat
IPR011989	ARM-like	Homologous_superfamily
IPR016024	ARM-type_fold	Homologous_superfamily
IPR021133	HEAT_type_2	Repeat
IPR033461	WRNPLPNID	Domain
IPR051023	PP2A_Regulatory_Subunit_A	Family

Pfam: PF02985, PF15017

UniProt features (25 total): repeat 14, sequence variant 4, region of interest 3, chain 1, compositionally biased region 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TF05-F1	73.55	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 935

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 170 (showing top): MODULE_52, MODULE_503, WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN, MODULE_195, ATGCTGG_MIR338, MODULE_147, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, SESTO_RESPONSE_TO_UV_C5, CCCAGAG_MIR326, IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP, DR3_Q4, MODULE_356, MARSON_BOUND_BY_FOXP3_STIMULATED, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS, AGGTGCA_MIR500

GO Biological Process (2): protein phosphorylation (GO:0006468), signal transduction (GO:0007165)

GO Molecular Function (3): protein phosphatase regulator activity (GO:0019888), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), protein phosphatase 4 complex (GO:0030289)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phosphorylation	1
protein modification process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
phosphoprotein phosphatase activity	1
phosphatase regulator activity	1
protein phosphatase binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
protein serine/threonine phosphatase complex	1

Protein interactions and networks

STRING

1249 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPP4R1	PPP4C	P33172	998
PPP4R1	PPP4R2	Q9NY27	971
PPP4R1	PPP4R4	Q6NUP7	795
PPP4R1	PPP4R3A	Q6IN85	785
PPP4R1	PIM2	Q9P1W9	646
PPP4R1	COBL	O75128	638
PPP4R1	PPP2CA	P05323	622
PPP4R1	PTPN9	P43378	602
PPP4R1	PPP6R2	O75170	579
PPP4R1	CSNK2A1	P19138	575
PPP4R1	PPP2R1B	P30154	573
PPP4R1	PPP4R3B	Q5MIZ7	568
PPP4R1	PPP6C	O00743	531
PPP4R1	PPP2CB	P11082	505
PPP4R1	CSNK2A2	P19784	496

IntAct

52 interactions, top by confidence:

A	B	Type	Score
PPP4R1	PPP4C	psi-mi:“MI:0915”(physical association)	0.930
C1S	C1R	psi-mi:“MI:0914”(association)	0.900
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
PPP2CB	STRN	psi-mi:“MI:0914”(association)	0.790
KIF1B	YWHAZ	psi-mi:“MI:0914”(association)	0.740
PPP4C	TCP1	psi-mi:“MI:0914”(association)	0.730
PPP2CB	CEP43	psi-mi:“MI:0914”(association)	0.730
PPP4C	SUPT5H	psi-mi:“MI:0914”(association)	0.640
RALBP1	JUN	psi-mi:“MI:0914”(association)	0.640
CCDC6	LZTS3	psi-mi:“MI:0914”(association)	0.530
PMPCB	AMY1A	psi-mi:“MI:0914”(association)	0.530
RALBP1	AP2B1	psi-mi:“MI:0914”(association)	0.530
PMPCB	PPP4R3A	psi-mi:“MI:0914”(association)	0.530
ANKRD22	ESYT2	psi-mi:“MI:0914”(association)	0.530
PPP4R1		psi-mi:“MI:0915”(physical association)	0.400
PPP4R1	HDAC3	psi-mi:“MI:0915”(physical association)	0.400
PPP4R1	CTNND1	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
	SUPT5H	psi-mi:“MI:0914”(association)	0.350
RALBP1	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
RALBP1	ABLIM1	psi-mi:“MI:0914”(association)	0.350
PPP2CA	ENSA	psi-mi:“MI:0914”(association)	0.350
PPP2CB	ENSA	psi-mi:“MI:0914”(association)	0.350

BioGRID (114): PPP4R1 (Two-hybrid), PPP4R1 (Affinity Capture-Western), TRAF2 (Affinity Capture-Western), PPP4R1 (Affinity Capture-MS), PPP4R1 (Affinity Capture-MS), PPP4R1 (Co-fractionation), PPP4R1 (Affinity Capture-MS), PPP4R1 (Affinity Capture-MS), CTNND1 (Affinity Capture-MS), LDHB (Affinity Capture-MS), NDUFB4 (Affinity Capture-MS), PPP2CA (Affinity Capture-MS), PPP2R1A (Affinity Capture-MS), PPP2R1B (Affinity Capture-MS), PPP4C (Affinity Capture-MS)

ESM2 similar proteins: A2AFR3, P54198, P70398, P86410, Q08BT5, Q14161, Q148V7, Q14CM0, Q3B7L5, Q3UGM2, Q5R660, Q5RAQ5, Q61666, Q66H91, Q68FF6, Q6DFZ1, Q6IC98, Q6P6Y1, Q6ZPY2, Q6ZWH5, Q76JQ2, Q7TPD0, Q8BHY8, Q8BIK4, Q8BQZ4, Q8CB44, Q8IWV8, Q8K2V1, Q8NFG4, Q8QZS3, Q8TF05, Q8VHE0, Q8VI02, Q8WXG6, Q91W96, Q92538, Q93008, Q96PE3, Q9BSQ5, Q9BZ29

Diamond homologs: G5ECH5, Q8K2V1, Q8TF05, Q8VI02, Q9P1A2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 54 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Mitotic Prometaphase	5	9.6×	3e-03
Signaling by Interleukins	5	8.9×	3e-03
Cytokine Signaling in Immune system	6	6.8×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

147 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	121
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3695 predictions. Top by Δscore:

Variant	Effect	Δscore
18:9549335:CAGT:C	acceptor_gain	1.0000
18:9550047:CTTA:C	donor_loss	1.0000
18:9550050:A:AC	donor_gain	1.0000
18:9550050:ACCTG:A	donor_loss	1.0000
18:9550051:C:CA	donor_loss	1.0000
18:9550051:C:CC	donor_gain	1.0000
18:9550051:CCTGG:C	donor_gain	1.0000
18:9550074:TGCCG:T	donor_gain	1.0000
18:9550182:CTGAC:C	acceptor_gain	1.0000
18:9550187:C:CG	acceptor_loss	1.0000
18:9550188:T:C	acceptor_loss	1.0000
18:9550195:G:C	acceptor_gain	1.0000
18:9550195:G:GC	acceptor_gain	1.0000
18:9550200:C:CT	acceptor_gain	1.0000
18:9550201:A:C	acceptor_gain	1.0000
18:9553320:A:AC	donor_gain	1.0000
18:9553321:C:CT	donor_gain	1.0000
18:9553321:CT:C	donor_gain	1.0000
18:9553321:CTCAG:C	donor_gain	1.0000
18:9553324:AG:A	donor_gain	1.0000
18:9553325:G:C	donor_gain	1.0000
18:9553423:C:CC	acceptor_gain	1.0000
18:9557216:GTTAC:G	donor_loss	1.0000
18:9557218:TACCT:T	donor_loss	1.0000
18:9557219:A:C	donor_loss	1.0000
18:9557220:C:CA	donor_loss	1.0000
18:9557255:AT:A	donor_gain	1.0000
18:9557256:T:C	donor_gain	1.0000
18:9557256:T:TA	donor_gain	1.0000
18:9557378:TTCCA:T	acceptor_gain	1.0000

AlphaMissense

6296 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:9547868:A:T	V925D	1.000
18:9550085:C:A	W838C	1.000
18:9550085:C:G	W838C	1.000
18:9550087:A:G	W838R	1.000
18:9550087:A:T	W838R	1.000
18:9550297:C:G	R798P	1.000
18:9550300:A:T	V797D	1.000
18:9550309:A:T	V794D	1.000
18:9550315:T:A	D792V	1.000
18:9550316:C:G	D792H	1.000
18:9550324:A:G	L789P	1.000
18:9550393:A:G	L766P	1.000
18:9553325:G:T	A763D	1.000
18:9553328:A:G	L762P	1.000
18:9553337:C:G	R759P	1.000
18:9553338:G:C	R759G	1.000
18:9553339:A:C	F758L	1.000
18:9553339:A:T	F758L	1.000
18:9553340:A:C	F758C	1.000
18:9553340:A:G	F758S	1.000
18:9553341:A:C	F758V	1.000
18:9553341:A:G	F758L	1.000
18:9553341:A:T	F758I	1.000
18:9553343:C:G	R757P	1.000
18:9553345:C:A	W756C	1.000
18:9553345:C:G	W756C	1.000
18:9553346:C:A	W756L	1.000
18:9553346:C:G	W756S	1.000
18:9553347:A:G	W756R	1.000
18:9553347:A:T	W756R	1.000

dbSNP variants (sampled 300 via entrez): RS1000018787 (18:9590864 G>A), RS1000221050 (18:9584929 G>A,C,T), RS1000234587 (18:9591116 G>A), RS1000406362 (18:9554749 G>A), RS1000434401 (18:9597882 A>C), RS1000455407 (18:9554986 C>T), RS1000479601 (18:9610977 C>A), RS1000520678 (18:9578636 A>G), RS1000557987 (18:9586472 T>C), RS1000585641 (18:9572027 A>G), RS1000682534 (18:9584966 A>G,T), RS1000710645 (18:9579704 C>T), RS1000860540 (18:9578203 T>C), RS1000943686 (18:9558948 G>A,T), RS1000970022 (18:9573352 T>A)

Disease associations

OMIM: gene MIM:604908 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST004616_34	Platelet distribution width	3.000000e-29
GCST008153_51	Lean body mass	9.000000e-06
GCST009391_175	Metabolite levels	5.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007984	platelet component distribution width
EFO:0004995	lean body mass
EFO:0010488	glycerol-3-phosphate measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	decreases expression, affects cotreatment, increases abundance, increases oxidation	2
triphenyl phosphate	affects expression	1
alpha-pinene	increases abundance, affects cotreatment, increases oxidation	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
decabromobiphenyl ether	decreases expression	1
kojic acid	increases expression	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
abrine	increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	increases expression	1
Acetaminophen	decreases expression	1
Acrolein	increases oxidation, increases abundance, affects cotreatment	1
Atrazine	decreases expression	1
Benzophenoneidum	increases expression	1
Caffeine	decreases phosphorylation	1
Endosulfan	increases expression	1
Folic Acid	decreases expression	1
Furaldehyde	decreases expression, affects cotreatment	1
Ivermectin	decreases expression	1
Lead	affects expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Sodium Chloride	affects cotreatment, decreases expression, affects localization	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Valproic Acid	affects expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TG22	HAP1 PPP4R1 (-) 1	Cancer cell line	Male
CVCL_TG23	HAP1 PPP4R1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists